Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis
(7h)
FDA Commissioner Marty Makary to resign, capping turbulent tenure: report
(10h)
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
(12h)
Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
(13h)
AstraZeneca’s $800M bet undermined by immunogenicity in phase 3
(14h)
BioPharma Dive
FDA chief Marty Makary resigns from agency, ending tumultuous tenure
(9h)
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
(11h)
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
(15h)
A year after Vertex’s big launch, pain drug research faces a pivotal moment
(16h)
GSK cuts deal with Sino to broaden reach of hepatitis B drug
(1d)
Endpoints News
Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options
(5h)
EU reaches provisional deal on Critical Medicines Act
(10h)
FDA Commissioner Makary to resign, source says
(10h)
Iran war disruptions begin to emerge upstream of the pharma supply chain
(10h)
What I learned at a journalism fellowship about covering healthcare AI
(11h)
BioSpace
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge
(14h)
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal
(15h)
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
(16h)
FDA turns to old drugs to address new diseases, persistent medical needs
(16h)
Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls
(1d)
STAT News
Why Marty Makary was the worst FDA commissioner in 25 years
(7h)
Males who discuss suicide seek help less often than females, report finds
(8h)
European Union inks a draft deal to boost local production of medicines and avoid shortages
(9h)
Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
(10h)
Supreme Court extends mifepristone deadline
(11h)
BioPharma Trend
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1d)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(4w)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(1mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(1mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(1mo)
Drug Channels
340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)
(17h)
The Hidden Costs of Over-Customizing Your Hub Technology Stack
(4d)
Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point
(1w)
Where Gross-to-net Pressure Actually Lives After Launch
(2w)
Drug Channels News Roundup, April 2026: PBM Specialty Pharmacy Steering, MLR Profit Shifting, Hospitals’ Fake Prices, and a Peek Behind the Scenes at DCI
(2w)
European Biotechnology Magazine
Infex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead asset
(16h)
EktaH links novel obesity drug to fat loss, muscle retention in early-phase trial
(19h)
Tolemy Bio raises €1.4m to build AI control panel for cell biology
(20h)
The DASbox® Mini Bioreactor System: Small scale. Big results
(2d)
Angelini inks $4.1B Catalyst takeover to fuel US expansion
(5d)
Drug Hunter
From Patient to Target: The Discovery of GDF15 in Hyperemesis Gravidarum
(12h)
Endometriosis Inspires Re-Examination of Known Targets at the Inaugural HERS Meeting
(1d)
Module 4, Section 3: Breakdown of Binding
(1d)
etripamil
(4d)
atirmociclib
(5d)
Labiotech.EU
Biotech risk management: The hidden risks behind layoffs
(14h)
The real reason CGT programs struggle to scale
(19h)
Inside CSL’s strategy to simplify a biotech giant
(1d)
The biggest biotech funding rounds in April 2026
(4d)
The rise of trispecific antibodies: Biopharma’s next big bet after bispecifics
(5d)
Bio IT World
AI Framework for Differentiating Neurodegenerative Diseases
(22h)
Trends from the Trenches: The Capability Jump of AI and Its Impact
(6d)
Bacteria: Unsung Players in the Tumor Microbiome
(7d)
Much Progress Needed Planning Research to Consider Sex as a Biological Variable
(1w)
Craig Venter, Genomics Pioneer and Visionary, Dies
(2w)
GEN News
10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit
(1h)
AAVs in Focus: Practical Approaches to Capsid Analytics and Plasmid DNA Control
(7h)
Brain Histamine Map Links Genetic Factors to Mental Health and Psychiatric Disorders
(8h)
Acute Myeloid Leukemia Therapy Improved by CRISPR Stem Cell Transplant
(8h)
Stable Producer Cell Line Generation Platform Adds to VIVEbiotech’s Lentiviral Vector Manufacturing Capabilities
(1d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(1mo)
Understanding High-Risk Essential Thrombocythemia
(1mo)
Son’s Decision to Donate Gave His Father a Second Chance
(1mo)
Functional Precision Medicine Advances Brain Tumor Care
(1mo)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(1mo)
Contract Pharma
AOP Health, VRG Therapeutics Unite to Advance Inflammation and Immunology Target
(7h)
Ribo, Insilico Medicine to Partner on AI-Driven siRNA Drug Development
(9h)
Lonza Launches Xcite AAV Producer Cell Line Platform
(12h)
Boehringer Ingelheim Advances Partnership with Brainomix to Improve Pulmonary Fibrosis Care
(12h)
Quantitative Biosciences Institute Taps Dr. John Young as Chief Strategy Officer
(13h)
Pharma Times
Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
(17h)
SMC backs first-line metastatic bladder cancer combination after trial results
(18h)
Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
(1d)
Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
(1d)
UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
(5d)
Medcity News
How Healthcare Leaders are Reacting to the White House’s Proposed Fertility Benefit Rule
(5h)
Inviting Investors and Corporate Business Development Leaders to Bullseye
(8h)
Sanford Health Continues M&A Push with North Memorial Health Deal
(8h)
Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B
(9h)
Five Ways Technology Can Transform Chronic Care Management
(13h)
Chemical & Engineering News
Marty Makary leaves a mixed legacy as FDA commissioner
(4h)
Helium supplies are tight—and it could get worse
(6h)
Business Watch: Massive complex planned for Abu Dhabi; Angelini to buy Catalyst for $4.1 billion
(7h)
Advances in imaging tools offer spatial biology for the AI age
(7h)
How a Canvas hack forced chemists to communicate creatively
(9h)
The Pharma Letter
Hengrui Pharma strikes $15.2 billion asset deal with BMS
(12h)
Strong start to 2026 for Lundbeck, with 21% revenue growth
(13h)
Bayer beats estimates to send shares higher
(13h)
FDA acts to make most of drug repurposing opportunities
(14h)
Cellular Intelligence acquires Novo Nordisk's cell therapy program for Parkinson's
(14h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(1mo)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(1mo)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(1mo)
Treating Triple Negative Breast Cancer in the Frontline Setting
(1mo)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(1mo)
MedWatch
Analyst expects strong Vimkunya results after Bavarian's raised forecast
(14h)
WS Audiology puts faith in own brands despite Italian-Danish megadeal
(15h)
WS Audiology lags behind in key business area and goes all in on next wave of products
(15h)
Coloplast CFO on major write-down: "We've never seen anything like this"
(16h)
Lundbeck raises its full-year guidance
(16h)
In The Pipeline
More Vague, But More Useful
(5h)
Those Pesky Post Translational Modifications
(1d)
The Latest News in Vaccine Obstruction
(5d)
Ubiquitin Rides Again
(1w)
Helium and the Strait of Hormuz
(1w)
Pharmaphorum
Reports: Makary out, Diamantas in as FDA commissioner
(9h)
Isomorphic raises $2.1bn for AI drug hunt
(12h)
Boehringer, Brainomix plan new trial of lung fibrosis AI
(14h)
EU agrees plan to tackle essential medicine shortages
(15h)
Novo says high-dose Wegovy can cause 28% weight loss
(16h)
Drug Discovery Weekly
Introducing Benchling Biologics: AI infrastructure for modern drug discovery (Americas Session)
(14h)
Introducing Benchling Biologics: AI infrastructure for modern drug discovery (Europe Session)
(14h)
How strong is the UK’s advanced therapy sector?
(14h)
Therapy for X-CGD shows early promise, Ensoma reports
(14h)
DDW Highlights: 12 May 2026
(16h)
HIT Consultant
Included Health Launches Provider Connect AI Assistant for High-Quality Physician Matching
(11h)
Labcorp Integrates Full Diagnostic Menu into Epic Aura: Streamlining Lab Workflows for U.S. Health Systems
(12h)
Medbridge Launches Outcomes Offering: Connecting Patient Care to Clinical Efficacy and Payment
(14h)
Evolution Devices Announces First Multi-Site Clinical Sale of EvoWalk to Sheltering Arms Institute
(14h)
1upHealth Deploys All CMS-0057-F Interoperability and Prior Authorization APIs Ahead of 2027 Deadline
(14h)
Insights: Pink Sheet
White House MFN Push In Foreign Markets Could Backfire On US, Limit Access
(4h)
US FDA OTP Chief Says Cell And Gene Therapy CMC Readiness Remains Key Roadblock
(7h)
Germany Aims To Link Drug Rebates To Local R&D Activity
(8h)
Makary Goes: Embattled US FDA Commissioner Resigns Amid White House, Special Interest Anger
(9h)
EU Joint Clinical Assessments: Could Zepzleca, Imdylltra or Itvisma Be Next?
(12h)
BioXconomy
Compliance updates—False Claims Act, MFN, FDA clinical trial results and 340B
(6h)
Executive appointments in biopharma legal roles
(8h)
DOJ declares ‘war on fraud’ on pharma as enforcement priorities shift
(12h)
Parexel buys pharmacovigilance tech firm Vitrana in latest AI-focused deal
(13h)
Eyes on Asia: BeOne Medicines, Takeda, GSK
(17h)
BioCentury
Solving AAV’s one-and-done problem: ASGCT highlights
(1d)
Thin ice for Makary, redosing AAVs — a BioCentury podcast
(1d)
GSK takes rights to cardiovascular program from China-based SiranBio: Deals Report
(1d)
Entrada, enGene lose over half their value on clinical readouts
(1d)
Makary’s grip slips at FDA, triggering speculation on successor
(4d)
SCRIP
Makary’s Exit Resurrects Questions About US FDA’s Direction Under Trump Administration
(3h)
Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH
(5h)
Rigel Will Take Over Pfizer/Arvinas’s Recently Approved Veppanu
(5h)
Where No One Has Gone Before: Enterprise Targets ENaC Success With ETD001
(7h)
Scrip Awards Podcast: Call For Entries 2026, New AI Category, Triana Interview
(12h)